Does insulin resistance raise remnant lipoproteins and small dense LDL to increase ASCVD risk even when hs-CRP is low?

This assessment examines the relationship between insulin resistance, atherogenic lipoproteins, and cardiovascular risk, specifically focusing on the persistence of this risk in the absence of systemic inflammation.

Lipid Dysregulation and Insulin Resistance

Insulin resistance (IR) is a primary driver of a characteristic dyslipidemic profile characterized by elevated triglycerides and early dysglycemia. Mechanistically, this occurs through multiple pathways:

• VLDL Overproduction: In the liver, IR impairs the normal insulin-mediated suppression of FoxO1 activity. This failure leads to the induction of microsomal triglyceride transfer protein (MTTP), facilitating the increased assembly and secretion of very-low-density lipoproteins (VLDL).
• Impaired Clearance: IR induces apolipoprotein CIII (apoCIII), which inhibits the catabolism of triglyceride-rich lipoproteins (TRLs). Additionally, IR is associated with increased intestinal secretion of apoB-48-containing TRLs and impaired clearance mechanisms.
• sdLDL Formation: Elevated triglyceride levels promote lipid exchange between VLDL and LDL. Subsequent hydrolysis by hepatic lipase (HL) transforms these triglyceride-enriched LDL particles into cholesterol-depleted, small dense LDL (sdLDL) particles, which have a higher propensity for arterial infiltration.

Cardiovascular Risk and Systemic Inflammation

The atherogenic risk posed by remnant lipoproteins and sdLDL persists independently of inflammatory markers.

• Direct Pathogenicity: Remnant cholesterol (RC) and sdLDL are potent predictors of atherosclerotic cardiovascular disease (ASCVD). sdLDL particles are particularly dangerous due to their ability to easily penetrate arterial walls, high susceptibility to oxidation, and prolonged circulation time.
• Independence from hs-CRP: Evidence from large cohorts, such as the Multi-Ethnic Study of Atherosclerosis (MESA), indicates that the cardiovascular risk conferred by remnants and sdLDL remains significant even when high-sensitivity C-reactive protein (hs-CRP) is low (e.g., <2 mg/L).
• Mechanistic Divergence: While systemic inflammation (high hs-CRP) compounds risk, the pro-atherogenic effects of remnants and sdLDL operate through distinct pathways—primarily direct lipid accumulation and oxidative stress—rather than being entirely dependent on the systemic inflammatory state.

Bottom line

Insulin resistance creates a highly atherogenic environment by increasing remnant lipoproteins and small dense LDL. These particles amplify cardiovascular risk through direct arterial damage and oxidation, maintaining their pathogenicity even in patients with low systemic inflammation as measured by hs-CRP.